BEAMBeam Therapeutics Inc.
Beam Therapeutics Inc. (BEAM) sells gene-editing therapies for rare genetic diseases, with a focus on sickle cell disease and phenylketonuria (PKU). Its next catalyst is Nov 16, 2026 — Sickle Cell Disease Program Regulatory Update & BLA Path, which will test the company’s ability to secure a Biologics License Application for its lead candidate. The event will gauge regulatory momentum and the strength of its clinical data in the U.S. FDA review process.
- Revenue surged 120% YoY to $50.39M, but net income remains -$424.04M, reflecting heavy R&D investment.
- Free cash flow is -$789.56M TTM, and debt-to-equity is 0.08x, signaling low leverage.
- Shareholders’ equity stands at $1.24B, with a diluted EPS of -$1.18, highlighting the company’s focus on long-term value over short-term profit.
The Read
BEAM's stock historically moved about 14%.5% on dosing events and mixed catalysts, falling 11.9% after weak earnings and competitive concerns, then slipping 14.6% due to a patent dispute, and dropping 18%.6% after missing revenue targets despite pipeline progress.
The schedule
- Mon16Nov
Critical regulatory update regarding the viability and BLA submission timeline for the risto-cel sickle cell program.
- Thu10Dec
Interim safety readout and enrollment progress for the AATD pivotal trial.
- Sun31Jan
Evaluation of the company's Q3 operating expenses and confirmation of the $1.2B cash runway.
- Tue9Feb
Year-end financial results and establishment of 2027 R&D and clinical milestones.
- Thu6May
First quarter financial update and continued scrutiny of clinical execution.
- Thu5Aug
Past
- Thu10Sep
Actual outcome: Bear · $23.26 at outcome
The stock fell 4.6% following the initiation of the Global Pivotal Cohort for BEAM-302, indicating investor concern. The price dropped below the bear floor, reflecting skepticism about the trial's potential impact on the company's valuation and future prospects.
Expected dosing of the first patient in the BEAM-302 pivotal cohort, a critical validation step for the base editing platform.
- Tue4Aug
Actual outcome: Bear · $27.25 at outcome
Beam Therapeutics reported a wider-than-expected Q2 loss and missed revenue estimates, which overshadowed its clinical pipeline updates. Although the company announced the first patient dosed in its BEAM-302 pivotal cohort and an upcoming late-breaking data presentation, the financial misses and operating burn concerns drove the stock below the bear floor.
Quarterly financial results, focusing on BEAM-302 clinical pipeline progression and operating burn.
- Wed15Jul
Actual outcome: Bear · $26.31 at outcome
The stock fell 14.6% and broke well below the bear floor, driven by negative developments leading up to the event window. Specifically, rival Prime Medicine secured a favorable arbitration ruling against Beam Therapeutics in a patent dispute over an alpha-1 antitrypsin deficiency (AATD) gene editing program, overshadowing any potential strategic partnership updates.
Assessment of capital raising options or non-dilutive partnerships given the stock's proximity to its 52-week highs.
- Thu7May
Actual outcome: Mixed · $31.75 at outcome
Beam Therapeutics reported a wider-than-expected Q1 loss of $0.91 per share, though revenues beat estimates and the company highlighted a strong $1.2 billion cash runway extending into mid-2029. Despite positive pipeline updates, including strong safety and efficacy data for BEAM-302 in AATD, the mixed financial results led to a muted 0.9% price increase, leaving the stock trading sideways between its bull and bear targets.
- Tue24Feb
Actual outcome: Bear · $28.48 at outcome
Despite Beam Therapeutics posting a narrower-than-expected Q4 loss, surging revenues, and securing $500 million in financing to extend its cash runway into mid-2029, the stock fell 11.9% and broke below the bear floor. The sell-off was driven by market concerns over the commercial viability of its sickle cell disease treatment, risto-cel, specifically regarding conditioning protocol challenges and stiff competition from Vertex and CRISPR Therapeutics.
